BKBohdan Khilchevskyi

Bohdan Khilchevskyi

*This is an algorithmically generated author record based on publicly available information.

Bohdan Khilchevskyi has a total of 7 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    OncoTagger: a reproducible abstract-level landscape of open-access AI-oncology articles in Web of Science

    by Bohdan Khilchevskyi, Polina Talapova, Denys Kaduk, Maksym Trofymenko, Tetiana Nesmiian

    AI-oncology evidence is expanding too quickly for static manual surveillance. We developed OncoTagger, a rule-based abstract-level evidence-surveillance pipeline, and applied it to an English-language, open-access article corpus indexed in the Web of Science Core Collection and analyzed at the title-, abstract-, keyword-, and metadata level from 2019 to 2025. From 59,994 initial records, deduplication, year restriction, automated screening, and manual adjudication yielded 20,766 records. Prediction-stratum-weighted corpus-level estimates showed metric-detection accuracy of 92.3% (95% CI 88.9–95.2%), sensitivity of 89.3% (85.4–93.3%), and specificity of 98.2% (94.5–100.0%). Ordinal metric categories showed exact agreement of 73.6% (69.0–77.8%) for the weighted-category output and 76.8% (72.3–80.8%) for the composite-metric output, with linear weighted Cohen’s kappa of 0.588 (0.513–0.659) and 0.615 (0.537–0.689), respectively. Primary-task assignment showed moderate agreement with manual consensus (68.0% exact agreement, 95% CI 63.3–72.4%; Cohen’s kappa 0.508, 0.442–0.572), and a complete task-unassigned census identified systematic dictionary-coverage gaps. The resulting resource describes abstract-reported metric patterns, pipeline-derived task mix, geography, and an exploratory candidate translational-signal subset. It should be interpreted as reproducible aggregate surveillance infrastructure, not as a full census of the AI-oncology field, a validated article-level classifier, or a comparative evaluation of algorithmic performance.

  • Open Access

    Rechallenge or switching to other CDK4/6 inhibitors in HR+/HER2–metastatic breast cancer after progression

    by O.S. Dudnichenko, B.S. Khilchevskyi, V.M. Lykhman, A.V. Kasianova

    Background. After progression on endocrine therapy combined with palbociclib in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer, a practical question arises regarding subsequent treatment: whether it is appropriate to reuse the same cyclin-dependent kinase inhibitor with a change in the endocrine partner, whether it is more rational to switch to another agent in this class, or whether to proceed only with the next line of endocrine therapy.Purpose – to assess the clinical appropriateness of palbociclib rechallenge and the strategy of switching cyclin-dependent kinase inhibitors after progression on palbociclib in metastatic breast cancer.Materials and Methods. A narrative literature review was performed. Sources were searched in PubMed/MEDLINE, Scopus, and ClinicalTrials.gov over the last seven years (2020–2026); supplementary searches for guidelines, congress materials, and regulatory documents were performed using Google Scholar. The analysis included randomized clinical trials, meta-analyses, reviews, and current clinical guidelines addressing treatment after progression on palbociclib.Results. The analysis showed that continuing therapy with the same inhibitor, particularly palbociclib, while changing the underlying endocrine therapy does not lead to a statistically significant improvement in progression-free survival, indicating the development of stable cross-resistance and making this approach clinically unjustified. In contrast, switching to another cyclin-dependent kinase inhibitor, primarily abemaciclib or ribociclib, is associated with more stable disease control and a more favorable balance between expected benefit and risk. It was additionally established that treatment selection after progression is increasingly determined by the molecular tumor profile, because alterations in estrogen receptor signaling, the phosphatidylinositol 3-kinase cascade, and loss of function of suppressor regulators may affect sensitivity to subsequent endocrine and targeted therapy, requiring the use of newer selective estrogen receptor degraders or targeted inhibitors.Conclusions. After progression on palbociclib, preference should be given not to routine rechallenge with the same drug, but to an individualized strategy involving a change of cyclin-dependent kinase inhibitor and consideration of the molecular characteristics of the tumor.